Skip to main content

Advertisement

SpringerLink
Log in

Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors

  • Brief Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Background

Treatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.

Methods

We described the treatment with this drug combination in a real-life cohort of 20 cirrhotic patients with genotype 1 who failed the triple therapy.

Results

18 of them (90%) with Child–Pugh A, 11 (55%) with genotype 1a, 17 (85%) with more than 1 and 8 (40%) with more than 2 previous failed treatment; all patients had at baseline NS3 resistance-associated variants related to triple therapy failure. RBV was not administered due to anemia in previous treatments. The sustained virological response was 100%.

Conclusion

Treatment with SOF + DCV without RBV for 24 weeks is safe and effective in cirrhotic patients who failed triple therapy with the first generation of protease inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

CHC:

Chronic hepatitis C

HCV:

Hepatitis C virus

PEG-IFN:

Pegylated interferon alfa

DAAs:

Direct-acting antiviral agents

TLV:

Telaprevir

BOC:

Boceprevir

DCV:

Daclatasvir

SOF:

Sofosbuvir

RBV:

Ribavirin

SVR:

Sustained virological response

IQR:

Inter-quartile range

References

  1. WHO. WHO fact sheet No. 164. 2012. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 25 July 2016

  2. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93.

    Article  CAS  PubMed  Google Scholar 

  3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.

    Article  CAS  PubMed  Google Scholar 

  4. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gerber L, Welzel TM, Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int. 2013;33:85–92.

    Article  CAS  PubMed  Google Scholar 

  6. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2013;383:515–23.

    Article  PubMed  Google Scholar 

  7. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Infectious Diseases, University of Turin, Turin, Italy

    Lucio Boglione, Simone Mornese Pinna, Chiara Simona Cardellino, Amedeo De Nicolò, Jessica Cusato, Chiara Carcieri, Giuseppe Cariti, Giovanni Di Perri & Antonio D’Avolio

  2. Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy

    Lucio Boglione, Simone Mornese Pinna, Chiara Simona Cardellino, Amedeo De Nicolò, Jessica Cusato, Chiara Carcieri, Giuseppe Cariti, Giovanni Di Perri & Antonio D’Avolio

Authors
  1. Lucio Boglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Mornese Pinna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Simona Cardellino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amedeo De Nicolò
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jessica Cusato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chiara Carcieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giuseppe Cariti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giovanni Di Perri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Antonio D’Avolio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucio Boglione.

Ethics declarations

Conflict of interest

The authors disclose no conflicts.

Ethical approval

“Kinetic-C protocol” approved by Ethical Committee “A. O. U. S. Luigi Gonzaga, Orbassano, Turin”, No. 186/14 in 26/5/2015.

Funding

This study was not supported.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boglione, L., Pinna, S.M., Cardellino, C.S. et al. Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. Infection 45, 103–106 (2017). https://doi.org/10.1007/s15010-016-0962-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-016-0962-3

Keywords

Search

Navigation